Loading...
Market
What type of new partnership or collaboration will Merck announce for Winrevair by June 30, 2025?
2
Resolution / Starting Odds
Pharmaceutical company • 25%
Research institution • 25%
Healthcare provider • 25%
No new partnerships • 25%
Official announcements from Merck or press releases from partner companies
Story
Merck's Winrevair Shows Positive Results in Phase 3 Trial, Reducing Risk of Death
Nov 25, 2024, 12:00 PM
Merck announced on Monday that its drug, Winrevair (sotatercept-csrk), has shown significant results in reducing the risk of death in patients with a rare lung condition that causes high blood pressure. The announcement follows the Pivotal Phase 3 ZENITH Trial, which met its primary endpoint at an interim analysis. This development comes months after the drug secured approval in the United States.
View original story
Similar markets
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No significant change • 25%
Decrease • 25%
